BiotechTube
Osel

Osel

Mountain View, United States· Est.
oselinc.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $11.5M

Overview

Osel is a pioneering, private biotech company developing a portfolio of Live Biotherapeutic Products (LBPs) to restore health by correcting microbiome imbalances (dysbiosis). With deep roots in the field, having filed its first IND in 2003, Osel's pipeline includes advanced programs in women's reproductive health and a groundbreaking oncology candidate, MO-03, which is set to begin a pivotal Phase 3 trial in combination with immunotherapy for kidney cancer. The company's strategy leverages its expertise in lactobacillus-based technology to address significant unmet medical needs in large markets, positioning it at the forefront of the emerging LBP sector.

OncologyWomen's HealthInfectious Disease

Technology Platform

Platform for developing Live Biotherapeutic Products (LBPs), with expertise in lactobacillus strains and bacterial formulation for vaginal and gastrointestinal delivery to modulate the microbiome and restore health.

Funding History

2
Total raised:$11.5M
Series A$10M
Seed$1.5M

Opportunities

The pivotal Phase 3 trial of MO-03 in kidney cancer represents a first-in-class opportunity to establish microbiome modulation as a standard adjunct to cancer immunotherapy, targeting a multi-billion dollar market.
In women's health, addressing recurrent bacterial vaginosis and preterm birth with a durable biologic solution targets large, chronic markets with significant unmet need and poor current standards of care.

Risk Factors

The company faces high clinical risk as its lead candidate enters a pivotal Phase 3 trial where failure would be catastrophic.
As a pre-revenue private company, it carries substantial financial and execution risk, dependent on external capital to fund expensive late-stage trials.
Regulatory and manufacturing complexity for novel Live Biotherapeutic Products adds further uncertainty.

Competitive Landscape

Osel competes in the emerging microbiome therapeutics space, facing competition from other biotechs developing bacterial consortia (e.g., Seres Therapeutics), engineered microbes (e.g., Synlogic), and fecal microbiota transplants for oncology. In women's health, competitors include companies like Locus Biosciences and academic groups developing lactobacillus-based therapies. Osel's first-mover advantage with a pivotal Phase 3 trial in oncology is a key differentiator.

More companies in Microbiome Therapeutics →More companies in United States →